Urological Tumor: A Narrative Review of Tertiary Lymphatic Structures

Urol Int. 2023;107(9):841-847. doi: 10.1159/000532127. Epub 2023 Sep 28.

Abstract

Background: Tertiary lymphoid structures (TLSs), as ectopic lymphoid-like tissues, are highly similar to secondary lymphoid organs and are not only involved in chronic inflammation and autoimmune responses but are also closely associated with tumor immunotherapy and prognosis. The complex composition of the urological tumor microenvironment not only varies greatly in response to immunotherapy, but the prognostic value of TLSs in different urological tumors remains controversial.

Summary: We searched PubMed, Web of Science, and other full-text database systems. TLSs, kidney cancer, uroepithelial cancer, bladder cancer, and prostate cancer as keywords, relevant literature was searched from the time the library was built to 2023. Systematically explore the role and mechanism of TLSs in urological tumors. It includes the characteristics of TLSs, the role and mechanism of TLSs in urological tumors, and the clinical significance of TLSs in urological tumors.

Key messages: The prognostic role of TLSs in different urological tumors was significantly different. It is not only related to its enrichment in the tumor but also highly correlated with the location of the tumor. In addition, autoimmune toxicity may be a potential barrier to its role in the formation of TLSs through induction. Therefore, studying the mechanisms of TLSs in autoimmune diseases may help in the development of antitumor target drugs.

Keywords: Immunotherapy; Markers; Tertiary lymphoid structures; Tumors; Urology.

Publication types

  • Review

MeSH terms

  • Humans
  • Kidney Neoplasms* / therapy
  • Male
  • Prognosis
  • Prostatic Neoplasms*
  • Tertiary Lymphoid Structures* / pathology
  • Tumor Microenvironment
  • Urinary Bladder Neoplasms* / therapy
  • Urologic Neoplasms* / therapy

Grants and funding

This study was supported by the Natural Science Foundation of Hebei Province (Grant No. H2021402018).